호흡기 진단 시장 : 제품 및 서비스별, 검사 유형별, 질환별, 진단 유형별 세계 예측(-2030년)

The global respiratory diagnostics market is projected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5% during the forecast period. The respiratory diagnostics market is driven by many rising impacts with respect to improving cases of respiratory diseases around the world. Innovative technologies in diagnosis, such as molecular diagnostics and advanced imaging solutions, have also improved the accuracy and speed of detection for conditions such as asthma, tuberculosis, or lung cancers. Increased awareness for healthcare providers and patients about the benefits of early diagnosis and more government-sponsored, healthy analysis programs have also served as important fuel sources in the demand for respiratory diagnostic solutions. The COVID-19 pandemic has demonstrated the need for efficient and reliable diagnostics in the management of respiratory infections. However, the market growth is restricted by several factors, including the recent changes in the regulatory framework concerning the approval of new products, their labeling requirements, and complete conformance to quality standards.

"Instruments and Devices segment accounted for the largest share in the respiratory diagnostics market."

The growing advancements in diagnosis technologies such as diagnostic imaging devices, spirometers, and other respiratory diagnostic instruments have led to such importance in this segment. In addition to this, the rising prevalence of respiratory disease across the globe has greatly increased the demand for advanced and accurate diagnostics tools. The innovations in point-of-care testing devices and portable diagnostic instruments, such as advanced point-of-care testing instruments and portable diagnostic instruments, have enhanced the growth of the Instrument and Devices segment, allowing rapid and accurate respiratory assessment by health professionals. Hence, the above factors are driving respiratory diagnostics market growth in the region.

"The Mechanical tests segment accounted for the largest share in the respiratory diagnostics market."

Mechanical tests, including tools like spirometers and peak flow meters, are essential for assessing lung function and airflow. The rising incidence of chronic respiratory conditions, such as asthma and COPD, has significantly increased the reliance on these diagnostic methods. Enhanced technological innovations, such as digital spirometry and portable devices, have improved the accuracy, ease of use, and accessibility of mechanical tests, making them more widely adopted in clinical and home settings. Furthermore, the growing emphasis on early diagnosis and continuous monitoring of respiratory health, particularly in managing chronic diseases, is a major driver for the expansion of this segment within the respiratory diagnostics market.

"Asthma segment accounted for the largest share in the global respiratory diagnostics market."

Increase accession of environmental pollutants, changing lifestyles, and genetic factors contributing to increasing cases in asthma which further necessitates the requirement of advanced diagnostic solutions. Asthma is one of the segments that include diagnostic modalities, pulmonary function tests, imaging techniques, and biomarker assessments, all of which comprise an option for asthma diagnosis and management. However, ongoing research and development initiatives focusing on personalized medicine drive the segment for respiratory diagnostics.

"Syndromic segment has accounted for the largest share in the global respiratory diagnostics market."

Syndromic segment holds the largest share in the respiratory diagnostics market due to its capabilities of rapid and widespread diagnosis for many pathogens from a single test. The efficiency is very important since in the management of conditions such as influenza and pneumonia, it is vital timeously to identify the causative agent for its effective treatment. Syndromic panels reduce the time in diagnosis and keep for diagnosis, as this promotes early interventions. At the same time, the applications of techniques such as PCR and multiplex assays have improved specificity and access to syndromic panels. Increasing need drives point-of-care testing in hospitals and clinics into adopting syndromic diagnostic solutions.

"Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market."

While respiratory diseases proliferate, there has been an surged awareness about the need for their early detection. This has in turn led to an increase in the diagnostic procedures carried out in most of these facilities. The segment Hospitals and Clinics cater to a wide range of diagnostic equipment and services such as imaging studies, pulmonary function tests, and molecular diagnostics; hence it offers a complete solution for respiratory health assessment. As a result, the segment positioning in this whole input-output course of illness diagnosis, management, and therapy clearly puts hospitals and clinics within this input-output chain addressing the emerging demand for respiratory diagnostics in many healthcare institutions.

"North America to witness the fastest CAGR in the respiratory diagnostics market during the forecast period."

Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America is expected to be in the leading position, holding the largest share of the global respiratory diagnostic market. This leadership position had been fueled by a highly developed healthcare system, along with high prevalence rates of respiratory diseases and considerable expenditure toward innovation in healthcare. According to their advanced diagnostic technologies, the focus is toward accurate and rapid testing; hence, they tend to give all of the parameters, including increased healthcare spending, larger aging populations, and strong emphasis on public health initiatives that are caused by respiratory issues, for example. Their overall regulatory framework encourages the adoption of these diagnostic solutions for continued growth.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 35%, Tier 2 - 40%, and Tier 3 - 25% * By Designation: C-level - 30%, Director-level - 23%, and Others - 47% * By Region: North America - 25%, Europe - 35%, APAC - 20%, Latin America - 13%, Middle East & Africa - 7%

Breakdown of demand-side primary interviews: * By Company Type: Hospitals & Clinics - 62%, Diagnostics Laboratories - 16%, and Other End Users - 22% * By Designation: Senior Managers - 35%, Chief Officers - 28%, Radiologists - 25% and Other Designations - 12% * By Region: North America - 32%, Europe - 25%, APAC - 20%, Latin America - 14%, Middle East & Africa - 9%

Research Coverage

This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

• Analysis of key drivers (increasing incidences of respiratory disorders, growing aging population and changing lifestyle, growing awareness about respiratory health, advancements in diagnostic technologies), restraints (high cost of diagnostic tests, limited reimbursement coverage, and lack of skilled professionals for advanced diagnostics), opportunities (increasing healthcare infrastructure and rising disposable incomes in emerging economies, rising demand for Point-of-care (POC) testing, and growing awareness of untreated sleep apnea), and challenges (complexity in diagnosing viral respiratory infections, and limited access to peripheral lung lesions in bronchoscopy) influencing the growth of respiratory diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary research objectives
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
  • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS
• 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023)
• 4.3 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX
• 4.4 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of respiratory disorders
    • 5.2.1.2 Expanding geriatric population and rise in sedentary lifestyles
    • 5.2.1.3 Growing awareness about respiratory health
    • 5.2.1.4 Advancements in diagnostic technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of diagnostic tests
    • 5.2.2.2 Limited reimbursements
    • 5.2.2.3 Shortage of skilled professionals
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
    • 5.2.3.2 Increasing demand for POC testing
    • 5.2.3.3 Growing awareness about untreated OSA
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complexities associated with diagnosis of viral respiratory infections
    • 5.2.4.2 Limited access to peripheral lung lesions in bronchoscopy
• 5.3 INDUSTRY TRENDS
  • 5.3.1 POINT-OF-CARE TESTING
  • 5.3.2 PERSONALIZED MEDICINE
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Home-based & personal DHTs
    • 5.4.1.2 PFT tools and molecular & imaging diagnostics
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 AI-enhanced imaging
    • 5.4.2.2 Serological & telehealth platforms
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Rapid respiratory diagnostic tests
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY ANALYSIS
  • 5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6.2 REGULATORY LANDSCAPE
    • 5.6.2.1 North America
      • 5.6.2.1.1 US
      • 5.6.2.1.2 Canada
    • 5.6.2.2 Europe
    • 5.6.2.3 Asia Pacific
      • 5.6.2.3.1 India
      • 5.6.2.3.2 China
      • 5.6.2.3.3 Japan
    • 5.6.2.4 Latin America
    • 5.6.2.5 Middle East & Africa
• 5.7 PATENT ANALYSIS
  • 5.7.1 KEY PATENTS GRANTED
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA FOR HS CODE 901819
  • 5.8.2 EXPORT DATA FOR HS CODE 901819
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY KEY PLAYER (2024)
  • 5.9.2 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023
• 5.10 VALUE CHAIN ANALYSIS
• 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 KEY BUYING CRITERIA
• 5.12 KEY CONFERENCES & EVENTS, 2024-2025
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 ADJACENT MARKET ANALYSIS
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.19 INVESTMENT & FUNDING SCENARIO
• 5.20 REIMBURSEMENT SCENARIO
• 5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET

6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 INSTRUMENTS & DEVICES
  • 6.2.1 INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS TO DRIVE MARKET
• 6.3 ASSAYS & REAGENTS
  • 6.3.1 INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET
• 6.4 SERVICES & SOFTWARE
  • 6.4.1 INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 MECHANICAL TESTS
  • 7.2.1 PULMONARY FUNCTION TESTS
    • 7.2.1.1 Spirometry
      • 7.2.1.1.1 Diagnosis of COPD and pulmonary fibrosis to drive market
    • 7.2.1.2 Peak flow tests
      • 7.2.1.2.1 Ability to provide accurate lung function monitoring with non-invasiveness benefits to fuel uptake
    • 7.2.1.3 Other pulmonary function tests
  • 7.2.2 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS
    • 7.2.2.1 Large presence of untreated population to drive market
  • 7.2.3 OTHER MECHANICAL TESTS
• 7.3 IMAGING TESTS
  • 7.3.1 X-RAY
    • 7.3.1.1 Integration of AI into X-ray devices for enhanced imaging capabilities to drive market
  • 7.3.2 COMPUTED TOMOGRAPHY
    • 7.3.2.1 Rising focus on obtaining high-resolution CT images to boost demand
  • 7.3.3 MAGNETIC RESONANCE IMAGING (MRI)
    • 7.3.3.1 Ability to provide detailed lung images without radiation exposure to drive market
  • 7.3.4 POSITRON EMISSION TOMOGRAPHY (PET)
    • 7.3.4.1 Growing focus on detection & monitoring of treatment response to lung cancer to drive market
  • 7.3.5 OTHER IMAGING TESTS
• 7.4 TRADITIONAL DIAGNOSTIC TESTS
  • 7.4.1 IMMUNODIAGNOSTICS
    • 7.4.1.1 Rising demand for rapid disease diagnosis to fuel uptake
  • 7.4.2 BIOCHEMICAL TESTS
    • 7.4.2.1 Ability to accurately measure biomarkers in pneumonia and bronchitis infections to boost demand
  • 7.4.3 MICROSCOPY
    • 7.4.3.1 Inadequate sensitivity towards emerging viruses to restrain market
• 7.5 MOLECULAR DIAGNOSTIC TESTS
  • 7.5.1 POLYMERASE CHAIN REACTION (PCR)
    • 7.5.1.1 Development of portable and real-time PCR machines to drive market
  • 7.5.2 NUCLEIC ACID AMPLIFICATION TEST (NAAT)
    • 7.5.2.1 Rapid identification of viral, bacterial, and fungal infections to fuel demand
  • 7.5.3 IN SITU HYBRIDIZATION (ISH)
    • 7.5.3.1 Utilization of probes for pathogen detection to support market growth
  • 7.5.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
    • 7.5.4.1 High-throughput capabilities for rapid analysis of genetic data to propel market
  • 7.5.5 MICROARRAYS
    • 7.5.5.1 Detection of hepatitis C and respiratory viruses to support market growth
  • 7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS

8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE

• 8.1 INTRODUCTION
• 8.2 TUBERCULOSIS
  • 8.2.1 FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET
• 8.3 ASTHMA
  • 8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
• 8.4 LUNG CANCER
  • 8.4.1 NON-SMALL-CELL LUNG CANCER (NSCLC)
    • 8.4.1.1 Rising investments in advanced radiographic technologies to fuel market
  • 8.4.2 SMALL-CELL LUNG CANCER (SCLC)
    • 8.4.2.1 Growing emphasis on precision testing to drive market
  • 8.4.3 OTHER LUNG CANCERS
• 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • 8.5.1 ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR COPD DIAGNOSIS TO FUEL MARKET
• 8.6 PNEUMONIA
  • 8.6.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND
• 8.7 OTHER DISEASES

9 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE

• 9.1 INTRODUCTION
• 9.2 SYNDROMIC DIAGNOSIS
  • 9.2.1 DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET
• 9.3 ETIOLOGICAL DIAGNOSIS
  • 9.3.1 IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET
• 9.4 PROGNOSIS DIAGNOSIS
  • 9.4.1 ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH

10 RESPIRATORY DIAGNOSTICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET
• 10.3 DIAGNOSTIC LABORATORIES
  • 10.3.1 ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS TO BOOST DEMAND
• 10.4 LONG-TERM CARE & SPECIALTY CENTERS
  • 10.4.1 PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET
• 10.5 ACADEMIC & RESEARCH INSTITUTES
  • 10.5.1 FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH

11 RESPIRATORY DIAGNOSTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Growing accessibility to technologically advanced products to boost demand
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of COPD to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing public healthcare expenditure to foster market growth
  • 11.3.3 UK
    • 11.3.3.1 Rising establishment of hospitals and increasing number of surgical procedures to fuel market
  • 11.3.4 FRANCE
    • 11.3.4.1 High prevalence of smoking and increasing demand for respiratory devices to drive market
  • 11.3.5 ITALY
    • 11.3.5.1 Unfavorable amendments to healthcare policies to restrain market
  • 11.3.6 SPAIN
    • 11.3.6.1 Increasing demand for home healthcare services to support market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Availability of universal healthcare reimbursement policy to drive market
  • 11.4.3 CHINA
    • 11.4.3.1 High incidence of viral respiratory infections to propel market
  • 11.4.4 INDIA
    • 11.4.4.1 Expansion of leading medical device manufacturers and large target patient population to drive market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 High prevalence of chronic lung diseases to boost demand
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Expanding geriatric population and rising incidence of chronic respiratory conditions to fuel market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Favorable government initiatives for healthcare sector improvement to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising prevalence of obesity & hypertension to fuel uptake
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 11.6.2.1.1 Investments in advanced healthcare technologies to drive market
    • 11.6.2.2 United Arab Emirates (UAE)
      • 11.6.2.2.1 Rising prevalence of asthma to support market growth
    • 11.6.2.3 Other GCC Countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021-DECEMBER 2024
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.4.1 RANKING OF KEY MARKET PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Test type footprint
    • 12.5.5.5 Disease type footprint
    • 12.5.5.6 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 BRAND/PRODUCT COMPARISON
• 12.8 R&D EXPENDITURE OF KEY PLAYERS
• 12.9 COMPANY VALUATION & FINANCIAL METRICS
  • 12.9.1 FINANCIAL METRICS
  • 12.9.2 COMPANY VALUATION
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products & services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 BECTON, DICKINSON AND COMPANY
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products & services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 ABBOTT LABORATORIES
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products & services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 THERMO FISHER SCIENTIFIC INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products & services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product & service launches
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 GE HEALTHCARE TECHNOLOGIES, INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products & services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product & service launches & approvals
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Other developments
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 BIO-RAD LABORATORIES, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products & services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 BIOMERIEUX
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products & services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 REVVITY, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products & services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 SEEGENE INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products & services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches & approvals
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Expansions
      • 13.1.9.3.4 Other developments
  • 13.1.10 NIHON KOHDEN CORPORATION
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products & services offered
  • 13.1.11 VITALOGRAPH
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products & services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product & service launches & approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 SDI DIAGNOSTICS
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products & services offered
  • 13.1.13 RESMED INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products & services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
      • 13.1.13.3.2 Expansions
      • 13.1.13.3.3 Other developments
  • 13.1.14 SIEMENS HEALTHINEERS AG
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products & services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches
      • 13.1.14.3.2 Deals
      • 13.1.14.3.3 Expansions
  • 13.1.15 COSMED SRL
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products & services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches
      • 13.1.15.3.2 Deals
  • 13.1.16 HOLOGIC, INC.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products & services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product launches
      • 13.1.16.3.2 Deals
  • 13.1.17 QIAGEN N.V.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products & services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product launches
      • 13.1.17.3.2 Deals
      • 13.1.17.3.3 Other developments
• 13.2 OTHER PLAYERS
  • 13.2.1 MGC DIAGNOSTICS CORPORATION
  • 13.2.2 VISBY MEDICAL, INC.
  • 13.2.3 BRIOTA TECHNOLOGIES PVT. LTD.
  • 13.2.4 BIRD HEALTHCARE
  • 13.2.5 LOWENSTEIN MEDICAL SE & CO. KG
  • 13.2.6 PROAXSIS
  • 13.2.7 NDD MEDICAL TECHNOLOGIES
  • 13.2.8 COMPUMEDICS LIMITED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS